Valeant Acquires Amarin’s U.S. Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant adds the Parkinson's therapy Permax (pergolide) to its CNS business with the acquisition of Amarin Corp.'s U.S. pharma business, announced Feb. 12